Zimbabwe has rejected a significant American health deal worth 367 million US dollars (272 million pounds) spanning five years due to Washington's request for confidential information.
This move came to light following a internal memorandum dated December was leaked, revealing that President Emmerson Mnangagwa believed the agreement was "lopsided".
An official representative later explained that the United States was requesting genetic material for scientific study and profit while was unwilling to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate process of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more talks to reach a agreement agreeable to both sides so the country's critical HIV programme can proceed.
Broader Background
Zimbabwe's decision follows a similar case in Kenya, where a court blocked a related deal with the US after concerns were raised about the security of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the US government, but Trump claimed its spending was "inefficient" and his administration was pursuing direct bilateral deals to boost transparency and responsibility.
As per statements, 16 nations in Africa have to date agreed to similar agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," his statement read.
"Put simply, our country would supply the basic resources for medical research with no certainty that the final treatments would be available to our population if a new disease outbreak arise."
Sovereignty and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral deals were upending structures previously established through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This system is intended to ensure that when a country provides its samples, the benefits – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how future collaboration could be designed in a way that honours the sovereignty and dignity of each country."
Medical Community Response
Medical experts said it acknowledged the official position, but recommended that talks must proceed considering much of the nation's Aids initiatives depended on international support.
"In cases where specific concerns exist, such as those relating to data governance or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group commented.
The situation emphasises the ongoing debate between receiving crucial international aid and protecting local interests in an ever more interconnected world.